MX374409B - Derivados de etinilo como moduladores del receptor de glutamato metabotrópico. - Google Patents

Derivados de etinilo como moduladores del receptor de glutamato metabotrópico.

Info

Publication number
MX374409B
MX374409B MX2018000592A MX2018000592A MX374409B MX 374409 B MX374409 B MX 374409B MX 2018000592 A MX2018000592 A MX 2018000592A MX 2018000592 A MX2018000592 A MX 2018000592A MX 374409 B MX374409 B MX 374409B
Authority
MX
Mexico
Prior art keywords
sup
receptor modulators
glutamate receptor
metabotropic glutamate
sub
Prior art date
Application number
MX2018000592A
Other languages
English (en)
Other versions
MX2018000592A (es
Inventor
Antonio Ricci
Barbara Biemans
Daniel Rueher
Eric Vieira
Fionn O'hara
Georg Jaeschke
Lothar Lindemann
Wolfgang Guba
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2018000592A publication Critical patent/MX2018000592A/es
Publication of MX374409B publication Critical patent/MX374409B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal (AREA)

Abstract

La presente invención se refiere a compuestos de fórmula I: (ver Fórmula) en la que R1 es alquilo inferior, R2 es fenilo o piridinilo, en el que el átomo de N en el grupo piridinilo puede encontrarse en posiciones diferentes, n es 0, 1 ? 2, V/U son, independientemente, O o CH2, en los que V y U no pueden ser simultáneamente O, L es un grupo heteroarilo de cinco o seis elementos, seleccionado de entre: (ver Fórmulas) o a una sal o sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica o a su enantiómero y/o isómero óptico y/o estereoisómero correspondiente de los mismos. Los compuestos pueden utilizarse para el tratamiento de la enfermedad de Parkinson, la ansiedad, la emesis, el trastorno obsesivo-compulsivo, el autismo, la neuroprotección, el cáncer, la depresión y la diabetes de tipo 2.
MX2018000592A 2015-07-15 2016-07-11 Derivados de etinilo como moduladores del receptor de glutamato metabotrópico. MX374409B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15176854 2015-07-15
PCT/EP2016/066393 WO2017009275A1 (en) 2015-07-15 2016-07-11 Ethynyl derivatives as metabotropic glutamate receptor modulators

Publications (2)

Publication Number Publication Date
MX2018000592A MX2018000592A (es) 2018-04-24
MX374409B true MX374409B (es) 2025-03-04

Family

ID=53758003

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000592A MX374409B (es) 2015-07-15 2016-07-11 Derivados de etinilo como moduladores del receptor de glutamato metabotrópico.

Country Status (30)

Country Link
US (3) US10189848B2 (es)
EP (1) EP3322701B1 (es)
JP (1) JP6761821B2 (es)
KR (1) KR20180026438A (es)
CN (1) CN107580598B (es)
AR (1) AR105341A1 (es)
AU (1) AU2016292863B2 (es)
CA (1) CA2984711C (es)
CL (1) CL2018000036A1 (es)
CO (1) CO2017011174A2 (es)
CR (1) CR20180022A (es)
DK (1) DK3322701T3 (es)
ES (1) ES2733468T3 (es)
HR (1) HRP20191139T1 (es)
HU (1) HUE045145T2 (es)
IL (1) IL255096B (es)
LT (1) LT3322701T (es)
MA (1) MA42442B1 (es)
MX (1) MX374409B (es)
PE (1) PE20180356A1 (es)
PH (1) PH12018500106A1 (es)
PL (1) PL3322701T3 (es)
PT (1) PT3322701T (es)
RS (1) RS58929B1 (es)
RU (1) RU2721776C9 (es)
SI (1) SI3322701T1 (es)
TR (1) TR201909160T4 (es)
TW (1) TWI612962B (es)
UA (1) UA120463C2 (es)
WO (1) WO2017009275A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
TR201909160T4 (tr) 2015-07-15 2019-07-22 Hoffmann La Roche Metabotropik glutamat reseptörü modülatörleri olarak etinil türevleri.
WO2018015235A1 (en) 2016-07-18 2018-01-25 F. Hoffmann-La Roche Ag Ethynyl derivatives
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
RS66310B1 (sr) 2018-05-04 2025-01-31 Incyte Corp Čvrsti oblici inhibitora fgfr i procesi za njegovu pripremu
KR102956194B1 (ko) 2018-05-04 2026-04-23 인사이트 코포레이션 Fgfr 억제제의 염
CA3102326A1 (en) 2018-07-26 2020-01-30 Domain Therapeutics Substituted quinazolinone derivatives and their use as positive allosteric modulators of mglur4
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEP20247679B (en) 2019-10-14 2024-10-10 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
US11566028B2 (en) 2019-10-16 2023-01-31 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
MX2022006691A (es) 2019-12-04 2022-09-19 Incyte Corp Derivados de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr).
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
TW202313610A (zh) 2021-06-09 2023-04-01 美商英塞特公司 作為fgfr抑制劑之三環雜環
JP2026507865A (ja) * 2023-03-10 2026-03-06 ブライトシード・インコーポレイテッド ストレス調節用組成物および方法ならびにその使用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
WO2006125784A1 (en) 2005-05-24 2006-11-30 Laboratoires Serono S.A. Tricyclic spiro derivatives as crth2 modulators
CN101528711A (zh) 2006-08-31 2009-09-09 先灵公司 可用作抗细菌剂的乙内酰脲衍生物
KR20100033981A (ko) 2007-06-03 2010-03-31 벤더르빌트 유니버시티 벤즈아미드 대사성 글루타민산염 수용체5 양성 알로스테릭 조절자 및 이의 제조 및 사용방법
EP2262832A4 (en) 2008-02-01 2011-03-09 Ca Minister Health & Welfare MONOCLONAL ANTIBODIES TO EBOLA AND MARBURG VIRUSES
JP5518899B2 (ja) 2009-01-19 2014-06-11 フォンダツィオネ・イルクス・カ’グランダ−オスペダレ・マジョーレ・ポリクリニコ 抗微生物活性を有するメラノコルチンアナログ
EP2473525A4 (en) 2009-09-02 2013-08-21 Us Army MONOCLONAL ANTIBODIES AGAINST GLYCOPROTEIN OF EBOLA SUDAN BONIFACE VIRUS
CN102740699A (zh) 2009-09-04 2012-10-17 范德比尔特大学 用于治疗神经学上的功能失调的mglur4变构增效剂、组合物和方法
US8389536B2 (en) 2009-10-27 2013-03-05 Hoffmann-La Roche Inc. Positive allosteric modulators (PAM)
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8586581B2 (en) 2009-12-17 2013-11-19 Hoffmann-La Roche Inc Ethynyl compounds useful for treatment of CNS disorders
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US8772300B2 (en) 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
MY165141A (en) 2011-04-26 2018-02-28 Hoffmann La Roche Pyrazolidin-3-one derivatives
EA022019B1 (ru) 2011-04-26 2015-10-30 Ф.Хоффманн-Ля Рош Аг Этинильные производные в качестве положительных аллостерических модуляторов mglur5
AU2012258618B2 (en) 2011-05-26 2017-05-25 Sunovion Pharmaceuticals Inc. Metabotropic glutamate receptors 5 modulators and methods of use thereof
US20130123254A1 (en) 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
UA110995C2 (uk) 2011-10-07 2016-03-10 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як модулятори метаботропного глутаматного рецептора
UA110862C2 (uk) 2011-10-07 2016-02-25 Ф. Хоффманн-Ля Рош Аг Похідні етинілу як алостеричні модулятори метаботропного рецептора глутамату mglur 5
SI2875000T1 (sl) 2012-07-17 2017-01-31 F.Hoffmann-La Roche Ag Ariletinilni derivati
PE20150628A1 (es) 2012-10-18 2015-05-11 Hoffmann La Roche Derivados de etinilo como moduladores de la actividad del receptor mglur5
UA114008C2 (xx) 2012-10-18 2017-04-10 Похідні етинілу як модулятори активності рецептора mglur5
WO2014124560A1 (en) 2013-02-18 2014-08-21 Hua Medicine (Shanghai) Ltd. Mglur regulators
UY35400A (es) 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
SG11201602029VA (en) * 2013-09-25 2016-04-28 Hoffmann La Roche Ethynyl derivatives
TWI649310B (zh) 2014-01-10 2019-02-01 赫孚孟拉羅股份公司 乙炔基衍生物
SG10201806481XA (en) 2014-02-19 2018-09-27 Emergent Biosolutions Canada Inc Marburg monoclonal antibodies
CN104860941B (zh) 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
CR20160384A (es) 2014-02-25 2016-11-07 Hoffmann La Roche Derivados de etilino
WO2016054598A2 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
CN107207481B (zh) 2015-03-19 2020-03-03 豪夫迈·罗氏有限公司 作为mglur4的调节剂的3-(4-乙炔基苯基)六氢嘧啶-2,4-二酮衍生物
TR201909160T4 (tr) 2015-07-15 2019-07-22 Hoffmann La Roche Metabotropik glutamat reseptörü modülatörleri olarak etinil türevleri.
WO2018015235A1 (en) 2016-07-18 2018-01-25 F. Hoffmann-La Roche Ag Ethynyl derivatives

Also Published As

Publication number Publication date
RU2018103944A3 (es) 2019-12-13
MA42442A (fr) 2018-05-23
CA2984711C (en) 2023-08-29
UA120463C2 (uk) 2019-12-10
CN107580598B (zh) 2020-11-13
PT3322701T (pt) 2019-06-28
TW201707705A (zh) 2017-03-01
ES2733468T3 (es) 2019-11-29
TR201909160T4 (tr) 2019-07-22
IL255096A0 (en) 2017-12-31
US10189848B2 (en) 2019-01-29
CA2984711A1 (en) 2017-01-19
WO2017009275A1 (en) 2017-01-19
CO2017011174A2 (es) 2018-01-31
EP3322701A1 (en) 2018-05-23
US20210269452A1 (en) 2021-09-02
PH12018500106A1 (en) 2018-07-23
PL3322701T3 (pl) 2019-09-30
AU2016292863A1 (en) 2017-11-02
US11034699B2 (en) 2021-06-15
HRP20191139T1 (hr) 2019-09-20
CL2018000036A1 (es) 2018-06-29
MX2018000592A (es) 2018-04-24
CR20180022A (es) 2018-02-26
JP6761821B2 (ja) 2020-09-30
RS58929B1 (sr) 2019-08-30
US20190119290A1 (en) 2019-04-25
RU2721776C2 (ru) 2020-05-22
MA42442B1 (fr) 2019-07-31
AU2016292863B2 (en) 2020-03-05
JP2018524305A (ja) 2018-08-30
US12006323B2 (en) 2024-06-11
IL255096B (en) 2020-01-30
LT3322701T (lt) 2019-07-10
KR20180026438A (ko) 2018-03-12
US20180134721A1 (en) 2018-05-17
PE20180356A1 (es) 2018-02-21
DK3322701T3 (da) 2019-07-08
SI3322701T1 (sl) 2019-08-30
CN107580598A (zh) 2018-01-12
BR112017023084A2 (pt) 2018-07-10
EP3322701B1 (en) 2019-05-01
RU2721776C9 (ru) 2020-10-22
HUE045145T2 (hu) 2019-12-30
TWI612962B (zh) 2018-02-01
RU2018103944A (ru) 2019-08-16
AR105341A1 (es) 2017-09-27

Similar Documents

Publication Publication Date Title
PH12018500106A1 (en) Ethynyl derivatives as metabotropic glutamate receptor modulators
EA201590438A1 (ru) 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы
EA201691046A1 (ru) Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4)
MX2014004144A (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
MY163164A (en) Ethynyl derivatives as positive allosteric modulators of the mglur5
EA201391056A1 (ru) Гетероарильные соединения в качестве лигандов 5-htрецептора
EA201590699A1 (ru) Производные этинила в качестве модуляторов активности рецептора mglur5
PH12016500427A1 (en) Ethynyl derivatives
MY165141A (en) Pyrazolidin-3-one derivatives
PH12019500119A1 (en) Ethynyl derivatives
PH12015500346A1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
PH12015500496B1 (en) Ethynyl derivatives as modulators of mglur5 receptor activity
CY1118595T1 (el) Αρυλοαιθινυλο πυριμιδινες
TH170900A (th) สารอนุพันธ์เอไธนิล-อิมิดาโซลิน-2,4-ไดโอน ในฐานะเป็นตัวคุม mGluR4
TH1701007595A (th) อนุพันธ์เอไทนิลในฐานะโมดูเลเตอร์ของเมทาโบโทรปิกกลูตาเมตรีเซปเตอร์

Legal Events

Date Code Title Description
FG Grant or registration